Concepedia

Author

Tillmann Krahnke

Novartis (Switzerland)

Also Known As

Krahnke, Tillmann, T. Krahnke, Tillmann Krahnke

32

Publications

2K

Citations

15

H-Index

19

Concepts

All Affiliations

Novartis (Switzerland)Oregon Health & Science UniversityThe University of Texas MD Anderson Cancer CenterInsermCentre Hospitalier Universitaire de Poitiers
TK

About

Tillmann Krahnke is an author at Novartis (Switzerland) specializing in medicine, neuroscience, and geriatrics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

34

2

Social Sciences

1

1

18

3

Cognitive Science

1

1

18

4

Geriatrics

1

1

18

5

Neuroscience

1

1

18

Tillmann Krahnke

×

17

Publications

1.9K

Citations

15

H-Index

YearCitations

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Richard A. Larson, Brian Druker, François Guilhot,

Blood

2008

631

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

Jörge E. Cortes, Michele Baccarani, François Guilhot,

Journal of Clinical Oncology

2009

285

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

Lydia Roy, Joëlle Guilhot, Tillmann Krahnke,

Blood

2006

216

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment

Andreas Hochhaus, Brian Druker, Charles L. Sawyers,

Blood

2007

208

A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients

Joost van der Hoek, Wouter W. de Herder, Richard A. Feelders,

The Journal of Clinical Endocrinology & Metabolism

2004

142

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Hagop M. Kantarjian, Richard A. Larson, François Guilhot,

Cancer

2009

111

Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

Jana Podhorná, Tillmann Krahnke, Michael Shear,

Alzheimer s Research & Therapy

2016

85

The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients

Joost van der Hoek, Aart‐Jan van der Lelij, Richard A. Feelders,

Clinical Endocrinology

2005

59

A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study

Jörge E. Cortes, Michele Baccarani, François Guilhot,

Blood

2008

54

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, Brian Druker, Jörge E. Cortes,

Blood

2009

34

Page 1